Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSPGx tacrolimus pharmacogenetic dosing in pretransplant chronic kidney disease
2024-516596-32-00Phase 4Authorised
- Sponsor
- FIBHULP
- Start
- Jan 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tacrolimus in chronic kidney disease (CKD) and Kidney allograft status (RTx) (2 arms), sponsored by FIBHULP. Primary endpoint: Tacrolimus concentration in therapeutic range at day 4. Planned start Jan 2025; status: authorised.
02
Drugs
tacrolimus
03
Conditions
chronic kidney disease (CKD)Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2024-516596-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516596-32-00.